Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

• the present invention relates to a process for the preparation of 5-fluoro-lH-pyrazolo [3,4-b] pyridine-3-carbonitrile of the formula (I)
• WO 2009/018415 describes the synthesis of 5-fluoro-1H-pyrazolo [3,4-b] pyridin-3-amine.
• nicotinic acid A By selective dechlorination of nicotinic acid A to compound B, subsequent conversion into the amide C, its reduction to nitrile and the final cyclization with hydrazine hydrate, the 5-fluoro-lH-pyrazolo [3,4-b] pyridine core is built up.
• the following Scheme 1 illustrates the synthesis.
• the object of the present invention is to provide an efficient process with high yield for the preparation of 5-fluoro-lH-pyrazolo [3,4-b] pyridine-3-carbonitrile of the formula (I)
• T 1 is (C 1 -C 4 ) -alkyl
• the compound of the formula (II) is known from the literature and can be prepared in analogy to Example 20A in WO 00/06569.
• the cyclization of the 5-aminopyrazole derivative of the compound ( ⁇ ) with the aldehyde of the compound ( ⁇ ) to the compound of the formula (IV) is carried out in an inert solvent optionally in the presence of trifluoroacetic acid in a temperature range from + 50 ° C to + 200 ° C, preferably at + 80 ° C to + 140 ° C, at atmospheric pressure, within for example 10 to 80 hours, preferably within 48 to 72 hours.
• Inert solvents are, for example, alcohols such as methanol, ethanol, n-propanol or isopropanol, ethers such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, hydrocarbons such as benzene, toluene, xylene, hexane, cyclohexane or Petroleum fractions or other solvents acetonitrile or N, N-dimethylformamide, or mixtures of solvents. Dioxane is preferred.
• the formation of the amide (IV) - »(V) is carried out by reaction in an inert solvent with ammonia in a temperature range from 0 ° C to + 50 ° C, preferably from + 20 ° C to + 30 ° C, at atmospheric pressure or elevated Printing, within 24 to 72 hours.
• Inert solvents are, for example, alcohols, such as methanol, ethanol, n-propanol or isopropanol.
• alcohols such as methanol, ethanol, n-propanol or isopropanol.
• a solution of ammonia in methanol in a concentration of 5N to 7N is used.
• the dehydration of the amide (V) to the nitrile (I) is carried out in an inert solvent in the presence of a suitable base with a suitable dehydrating agent such as trifluoroacetic anhydride, acetic anhydride or trifluoromethanesulfonic anhydride, in a temperature range of 0 ° C to + 60 ° C, preferably at + 20 ° C to + 30 ° C, within 12 to 36 hours.
• a suitable dehydrating agent such as trifluoroacetic anhydride, acetic anhydride or trifluoromethanesulfonic anhydride
• Inert solvents are ethers such as diethyl ether, dioxane, tetrahydrofuran (THF), glycol dimethyl ether or diethylene glycol dimethyl ether, hydrocarbons such as benzene, toluene, xylene, hexane, cyclohexane or petroleum fractions or other solvents acetonitrile or N, N-dimethylformamide, or mixtures of solvents.
• THF tetrahydrofuran
• Suitable bases are, for example, organic amines such as triethylamine, diisopropylethylamine, pyridine, 1,8-diazabicyclo [5.4.0] undec-7-ene (DBU) or 1,5-diazabicyclo [4.3.0] non-5-ene (DBN). , Preference is given to pyridine.
• organic amines such as triethylamine, diisopropylethylamine, pyridine, 1,8-diazabicyclo [5.4.0] undec-7-ene (DBU) or 1,5-diazabicyclo [4.3.0] non-5-ene (DBN).
• DBU 1,8-diazabicyclo [5.4.0] undec-7-ene
• DBN 1,5-diazabicyclo [4.3.0] non-5-ene
• the compounds described in the context of the process according to the invention can also be present in the form of their salts, solvates or solvates of the salts.
• Suitable salts in the context of the invention are physiologically acceptable salts of the compounds used and prepared in the process according to the invention.
• Physiologically acceptable salts of the compounds used and prepared in the process according to the invention include acid addition salts of mineral acids, carboxylic acids and sulfonic acids, for example salts of hydrochloric acid, hydrobromic acid, sulfuric acid, Phosphoric, methanesulfonic, ethanesulfonic, toluenesulfonic, benzenesulfonic, naphthalenedisulfonic, acetic, propionic, lactic, tartaric, malic, citric, fumaric, maleic and benzoic acids.
• Physiologically acceptable salts of the compounds used and prepared in the process according to the invention also include salts of conventional bases such as, by way of example and by way of example, alkali metal salts (eg sodium and potassium salts), alkaline earth salts (eg calcium and magnesium salts) and ammonium salts derived from ammonia or organic amines with 1 to 16 C atoms, such as, by way of example and by way of preference, ethylamine, diethylamine, triethylamine, ethyldiisopropylamine, monoethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, dimethylaminoethanol, procaine, dibenzylamine, N-methylphosphine, dihydroabiethylamine, arginine, lysine, ethylenediamine and methylpiperidine.
• alkali metal salts eg sodium and potassium salts
• alkaline earth salts eg calcium and magnesium salts
• solvates are those forms of the compounds used and prepared in the process according to the invention which form a complex in the solid or liquid state by coordination with solvent molecules. Hydrates are a special form of solvates that coordinate with water.
• alkyl is a linear or branched alkyl radical having 1 to 4 carbon atoms. Examples which may be mentioned are: methyl, ethyl, ⁇ -propyl, isopropyl, ⁇ -butyl, isobutyl, ⁇ -butyl and tert-butyl.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=44651701

Family Applications (1)

Country Status (7)

Families Citing this family (8)

Family Cites Families (3)

• 2010
  • 2010-09-03 DE DE102010040234A patent/DE102010040234A1/de not_active Withdrawn
• 2011
  • 2011-08-31 CN CN2011800424588A patent/CN103080110A/zh active Pending
  • 2011-08-31 US US13/819,905 patent/US20130211090A1/en not_active Abandoned
  • 2011-08-31 CA CA2809912A patent/CA2809912A1/en not_active Abandoned
  • 2011-08-31 JP JP2013526458A patent/JP2013536826A/ja not_active Withdrawn
  • 2011-08-31 WO PCT/EP2011/065004 patent/WO2012028645A1/de active Application Filing
  • 2011-08-31 EP EP11757221.4A patent/EP2611803A1/de not_active Withdrawn

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events